NO20062916L - Overflatelokaliserte campylobacter jejuni-polypeptider - Google Patents

Overflatelokaliserte campylobacter jejuni-polypeptider

Info

Publication number
NO20062916L
NO20062916L NO20062916A NO20062916A NO20062916L NO 20062916 L NO20062916 L NO 20062916L NO 20062916 A NO20062916 A NO 20062916A NO 20062916 A NO20062916 A NO 20062916A NO 20062916 L NO20062916 L NO 20062916L
Authority
NO
Norway
Prior art keywords
campylobacter
polypeptides
campylobacter jejuni
localized
surface localized
Prior art date
Application number
NO20062916A
Other languages
English (en)
Norwegian (no)
Inventor
Janne Skaarup Crawford
Pia Nyborg Nielsen
Tatyana A Prokhorova
Petra Schrotz-King
Original Assignee
Ace Biosciences As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ace Biosciences As filed Critical Ace Biosciences As
Publication of NO20062916L publication Critical patent/NO20062916L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NO20062916A 2003-11-21 2006-06-21 Overflatelokaliserte campylobacter jejuni-polypeptider NO20062916L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301726 2003-11-21
US52461703P 2003-11-25 2003-11-25
PCT/DK2004/000803 WO2005049641A2 (en) 2003-11-21 2004-11-19 Surface-located campylobacter jejuni polypeptides

Publications (1)

Publication Number Publication Date
NO20062916L true NO20062916L (no) 2006-08-21

Family

ID=43426113

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062916A NO20062916L (no) 2003-11-21 2006-06-21 Overflatelokaliserte campylobacter jejuni-polypeptider

Country Status (14)

Country Link
US (1) US20070178110A1 (de)
EP (1) EP1694697B1 (de)
JP (1) JP2008501625A (de)
KR (1) KR20060129229A (de)
CN (1) CN1906210A (de)
AT (1) ATE493431T1 (de)
AU (1) AU2004291213B2 (de)
CA (1) CA2546873A1 (de)
DE (1) DE602004030824D1 (de)
DK (1) DK1694697T3 (de)
ES (1) ES2358804T3 (de)
NO (1) NO20062916L (de)
PL (1) PL1694697T3 (de)
WO (1) WO2005049641A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE545655T1 (de) * 2004-06-18 2012-03-15 Enkam Pharmaceuticals As Fgfr-bindende peptide
AU2006229549B2 (en) * 2005-03-31 2011-04-07 Leiden University Medical Center Methods and means for diagnostics, prevention and treatment of Mycobacterium infections and tuberculosis disease
CN102497875B (zh) * 2009-07-16 2014-08-20 华盛顿州立大学研究基金会 抑制空肠弯曲杆菌细菌感染的抗原组合物和方法及该抗原组合物的用途
MX350306B (es) 2010-06-09 2017-09-04 Univ Arkansas Vacuna y metodos para reducir una infeccion por campylobacter.
CN104159601B (zh) 2012-02-01 2017-05-24 代表亚利桑那大学的亚利桑那董事会 弯曲杆菌属免疫原性组合物及其用途
US10248758B2 (en) * 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
AU2014239557B2 (en) 2013-03-15 2019-01-03 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
KR102767638B1 (ko) 2016-05-03 2025-02-20 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
BR112019015425A2 (pt) 2017-01-27 2020-05-26 University Of Florida Research Foundation, Incorporated Uma vacina de segurança alimentar para controlar salmonella enterica e reduzir campylobacter em aves domésticas
EP3823727A2 (de) * 2018-07-17 2021-05-26 Humabs Biomed SA Antikörper gegen campylobacter-spezies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200344A (en) * 1990-11-13 1993-04-06 Blaser Martin J Diagnostic testing for campylobacter jejuni or campylobacter coli infections using novel antigens
NZ338039A (en) * 1997-04-01 2001-04-27 Human Genome Sciences Inc Identification of polynucleotides encoding helicobacter polypeptides in the helicobacter genome
AU3458299A (en) * 1998-03-31 1999-10-18 United States Of America, As Represented By The Secretary Of Agriculture, The Monoclonal antibodies against (campylobacter jejuni) and (campylobacter coli) outer membrane antigens
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
JP2000351735A (ja) * 1999-04-09 2000-12-19 Akzo Nobel Nv カンピロバクターワクチン
CA2296869A1 (en) * 2000-01-24 2001-07-24 Angela Joe A surface-exposed lipoprotein to campylobacter jejuni involved in adherence to hep-2 cells
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms

Also Published As

Publication number Publication date
EP1694697B1 (de) 2010-12-29
PL1694697T3 (pl) 2011-05-31
DK1694697T3 (da) 2011-04-18
US20070178110A1 (en) 2007-08-02
WO2005049641A2 (en) 2005-06-02
KR20060129229A (ko) 2006-12-15
HK1097854A1 (en) 2007-07-06
AU2004291213B2 (en) 2011-09-08
CA2546873A1 (en) 2005-06-02
ES2358804T3 (es) 2011-05-13
JP2008501625A (ja) 2008-01-24
ATE493431T1 (de) 2011-01-15
WO2005049641A3 (en) 2005-10-20
CN1906210A (zh) 2007-01-31
DE602004030824D1 (de) 2011-02-10
AU2004291213A1 (en) 2005-06-02
EP1694697A2 (de) 2006-08-30

Similar Documents

Publication Publication Date Title
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
NO20062916L (no) Overflatelokaliserte campylobacter jejuni-polypeptider
NO20065084L (no) Interferon-alfa polypeptider og konjugater
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
NO20006681D0 (no) Fremgangsmåte ved tidlig diagnose av karsinomer
WO2000029008A3 (en) Hiv-specific t-cell induction
NO20080590L (no) Humane, monoklonale antistoffer mot programmert dodsligand (PD-L1)
SI1576967T1 (sl) Rekombinantni protein, ki nosi epitope humanega papilomavirusa, vstavljene v adenilat ciklazni protein ali njegov fragment, in njegove terapevtske uporabe
WO2002016412A3 (en) Binding polypeptides for b lymphocyte stimulator protein (blys)
TR199800613A1 (xx) Nezle A��s�.
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
ATE450547T1 (de) Eml4-alk-fusionsgen
EP1281755A3 (de) Humane cyp2d6 Genvarianten
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
NO20065366L (no) Antistoffer og molekyler som er avledet fra disse som binder til STEAP-1-proteiner
NO20052363L (no) Interferon-alfa polypeptider og konjugater
ATE521627T1 (de) Identifikation kreuzreaktiver epitope des flavivirus-hüllglykoproteins
WO2002074237A3 (en) Compositions and methods for the therapy and diagnosis of kidney cancer
IL179441A0 (en) Hif prolyl hydroxylase activity assay
WO2006062402A3 (en) Heat shock proteins (hsp) and supraventricular arrhythmia
NO20063375L (no) Agonist-anti-trkC-antistoffer og fremgangsmater for a anvende disse
EP2083018A3 (de) Zusammensetzungen und Verfahren mit Bezug zu STOP-1
DE60132443D1 (de) In lebenden zielzellen
WO2002092765A3 (en) Novel telomerase inhibitors and uses therefor
DE60334008D1 (de) Reduzierter slam abhängiger zell eintritt

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application